"
Team:Wageningen UR/ModifyingtheCCMV
From 2012.igem.org
TSlijkhuis (Talk | contribs) |
Jeroenbosman (Talk | contribs) (→Outside modification of CCMV VLP) |
||
| Line 12: | Line 12: | ||
==== Outside modification of CCMV VLP ==== | ==== Outside modification of CCMV VLP ==== | ||
| + | To aid in a better and quicker response to newly emerging pathogens, a more standardized approach of vaccine production could help in containing pandemic outbreaks. Faster reaction in vaccine development and production could be achieved with a universal approach and giving vaccine developers the opportunity to adapt their process better to the demand using the newly developed Quality by Design approach. The focus will be on providing a universal approach for a connector system. The aim is to create a “Plug 'N Apply System". The concept is that only the epitopes need to be selected and produced, after which they can be applied upon one standard vaccination platform. These epitopes are fused to connector peptides. The production will be one standardized synthetic biology procedure, and produced in a single, production friendly organism. The connector peptide is able to “plug onto” a standardized platform, which then provides an expression surface ready for immunization of subjects. The standardized platform can be produced as a bulk reservoir to provide massive reserves of backbone for a sudden explosive demand of vaccine. The industry can shift their production according to the demand by solely selecting the epitope that they fuse to the connector. This will provide more flexibility and quicker response to emerging pathogenic threats | ||
==== inside modification of CCMV VLP ==== | ==== inside modification of CCMV VLP ==== | ||
Revision as of 08:50, 20 July 2012
Contents |
Part 1: Modifying the CCMV VLP for site specific drug delivery
Introduction
CCMV will be one of the VLPs that we will be working on. We will focus on this VLP to prove the concept of using it as a Drug Delivery System.
Aim: Producing CCMV VLPs with epitopes on the outside or packaging coils in the inside, with the possibility to combine both to deliver a bio Nano carrier, with ligands on the outside and “medicine” packed on the inside.
Outside modification of CCMV VLP
To aid in a better and quicker response to newly emerging pathogens, a more standardized approach of vaccine production could help in containing pandemic outbreaks. Faster reaction in vaccine development and production could be achieved with a universal approach and giving vaccine developers the opportunity to adapt their process better to the demand using the newly developed Quality by Design approach. The focus will be on providing a universal approach for a connector system. The aim is to create a “Plug 'N Apply System". The concept is that only the epitopes need to be selected and produced, after which they can be applied upon one standard vaccination platform. These epitopes are fused to connector peptides. The production will be one standardized synthetic biology procedure, and produced in a single, production friendly organism. The connector peptide is able to “plug onto” a standardized platform, which then provides an expression surface ready for immunization of subjects. The standardized platform can be produced as a bulk reservoir to provide massive reserves of backbone for a sudden explosive demand of vaccine. The industry can shift their production according to the demand by solely selecting the epitope that they fuse to the connector. This will provide more flexibility and quicker response to emerging pathogenic threats
